Scientists are working on a way to ‘silence’ a genetic flaw that increases the risk of heart attacks.
The defect raises the amount of a fatty protein called Lipoprotein (a), which is found in potentially dangerous levels in 20 per cent of the population.
It causes blood to clot too easily and cannot be controlled by lifestyle changes.
Researchers are trying to develop new ways of bringing levels down using so-called ‘RNA inhibitors’.
Scientists are working on a way to ‘silence’ a genetic flaw that increases the risk of heart attacks
The aim is to develop a long-lasting injectable drug given only a couple of times a year.
First new oral treatment for high cholesterol in a decade approved by NICE
Bempedoic acid has been approved for routine NHS prescribing with ezetimibe to treat primary hypercholesterolaemia or mixed dyslipidaemia when statins are unsuitable.
by Chloe Harman
Sign in to continue
Free email bulletins